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Eleven (48%) of the episodes had a sHTN event after the 
initial Labetalol dose. The timing of recurrence of sHTN
event occurred in the first hour in 39% of the 23 episodes. 
48% of the 23 episodes did not have a sHTN event 
following the initial treatment for the duration of the 
episode. (see figure 1)
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There is a rising concern as hypertensive 
conditions increase in pregnant women in the 
United States. Even more concerning, the 
Centers for Disease Control report that 6.8% of 
maternal deaths in the United States from 
2011-2015 were attributed to hypertension 
disorders of pregnancy. Expert opinion 
treatment protocols have been developed in an 
effort to reduce mortality from pregnancy 
related hypertensive disorders. 
In 2017 the American College of Obstetricians 
and Gynecologists (ACOG) recommended a 
standardized approach for management of 
severe hypertension which requires close 
monitoring by clinical staff and a minimum of 
16 follow up blood pressure (BP) checks for 
patients in seven hours. This protocol calls for 
reassessing blood pressures every 10 minutes 
for one hour, then, every 15 minutes for one 
hour, then, every 30 minutes for one hour, then 
every 60 minutes for four hours. 
This study was conducted at the 523-bed 
Providence St. Vincent Medical Center in the 
Perinatal Special Care Unit (PSCU), a 15 bed 
unit that uses the ACOG protocol. There is no 
existing empirical data to support the current 
practice.
A retrospective chart review was completed on 28 patients 
who were treated with Labetalol for severe hypertension, 
systolic blood pressure (SBP) ≥160 or diastolic blood 
pressure (DBP) ≥105, during the postpartum phase 
between 09/30/2017 and 12/14/2017. 
All postpartum patients within 42 days of delivery requiring 
treatment for severe hypertension (sHTN), including 
teenagers and prisoners, were eligible for inclusion. 
Patients requiring treatment for sHTN only in the 
antepartum and/or intrapartum phase were excluded.
The study sample was reduced to 16 subjects as 12 
subjects did not meet the study inclusion criteria. Of those 
16 subjects, five had more than one sHTN episode. These 
16 patients experience a total of 23 sHTN episodes. 
An episode is defined as the time it takes to complete the 
7 hours of follow up BP checks without re-intervention due 
to a sHTN event. If the patient had another sHTN event 
that required treatment then the 7 hours of follow up BP 
checks restarts. A sHTN event is any SBP ≥160 or DBP 
≥105. Treatment for a sHTN event during an episode will 
vary by timing within the episode, prior treatment and 
provider.
This review looked only at the first dose of Labetalol for 
each episode and the timing of the next subsequent sHTN
event following that dose. Labetalol was selected as it is 
the most common first-line medication used in the PSCU. 
This pilot demonstrates a straightforward 
methodology to evaluate recurrence and timing of 
severe hypertension following treatment. Using 
this methodology of looking at the timing of follow 
up severe blood pressure after treatment appears 
to be reasonable method for further evaluation in 
a larger study population.
A larger study population would allow for 
statistical consideration of important variables 
such as severity of the blood pressures, variety of 
treatments including but not limited to Labetalol, 
diagnosis, concurrent medications, co-morbidities, 
caregiver variation, demographics, cuff size and 
location, and patient positioning. 
This strict regime based on expert opinion is a 
burden to patients and staffing resources. A 
methodology is needed in order to review the 
evidence to support or change this practice.
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Figure 1. Incidence of severe hypertensive (sHTN) event after initial dose on Labetalol
Hour 1: 
check every 10 min
Hour 2: 
check every 15 min
Hour 3: 
check every 
30 min
Hours 4-7: 
check every 60 min
Other first-line medications to treat sHTN include 
Hydralazine and Nifedipine it would be important 
to study the effects of these medication as well. 
Study investigators plan to apply this study 
methodology to a larger population to compose a 
robust evidence pool to support the current blood 
pressure reassessment protocol or suggest an 
alternative. 
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There is a rising concern as hypertensive 
conditions increase in pregnant women in the 
United States. Even more concerning, the 
Centers for Disease Control report that 6.8% of 
maternal deaths in the United States from 2011-
2015 were attributed to hypertension disorders of 
pregnancy. Expert opinion treatment protocols 
have been developed in an effort to reduce 
mortality from pregnancy related hypertensive 
disorders. 
In 2017 the American College of Obstetricians 
and Gynecologists (ACOG) recommended a 
standardized approach for management of severe 
hypertension which requires close monitoring by 
clinical staff and a minimum of 16 follow up blood 
pressure (BP) checks for patients in seven hours. 
This protocol calls for reassessing blood 
pressures every 10 minutes for one hour, then, 
every 15 minutes for one hour, then, every 30 
minutes for one hour, then every 60 minutes for 
four hours. 
This study was conducted at the 523-bed 
Providence St. Vincent Medical Center in the 
Perinatal Special Care Unit (PSCU), a 15 bed unit 
that uses the ACOG protocol. There is no existing 
empirical data to support the current practice.
Any postpartum patient within 42 days of delivery 
requiring treatment for severe hypertension 
(sHTN), including teenagers and prisoners, was 
eligible for inclusion. Patients requiring treatment 
for sHTN only in the antepartum and/or 
intrapartum phase were excluded.
The study sample was reduced to 16 subjects as 
12 subjects did not meet the study inclusion 
criteria. Of those 16 subjects, five had more than 
one sHTN episode. Total number of sHTN
episodes for these16 patients was 23. 
An episode is defined as the time it takes to 
complete the 7 hours of follow up BP checks 
without re-intervention due to a sHTN event. If the 
patient had another sHTN event that required 
treatment then the 7 hours of follow up BP checks 
restarts. A sHTN event is any SBP ≥160 or DBP 
≥105. Treatment for a sHTN event during an 
episode will vary by timing within the episode, 
prior treatment and provider.
This review looked only at the first dose of 
Labetalol for each episode and the timing of any 
subsequent sHTN event following that dose. 
Labetalol was selected as it is the most common 
first-line medication used in the PSCU. If the 
patient was re-medicated during the episode, the 
investigators did not explore this variable. 
This pilot demonstrates a straightforward 
methodology to evaluate recurrence and timing of 
severe hypertension following treatment. Using 
this methodology of looking at the timing of follow 
up severe blood pressure after treatment appears 
to be reasonable method for further evaluation in 
a larger study population. 
This strict regime based on expert opinion is a 
burden to patients and staffing resources. A 
methodology is needed in order to review the 
evidence to support or change this practice.
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A retrospective chart review was completed on 28 
patients who were treated with Labetalol for 
severe hypertension, systolic blood pressure 
(SBP) ≥160 or diastolic blood pressure (DBP) 
≥105, during the postpartum phase between 
09/30/2017 and 12/14/2017. 
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A larger study population would allow for 
statistical consideration of important variables 
such as severity of the blood pressures, variety of 
treatments including but not limited to Labetalol, 
diagnosis, concurrent medications, co-
morbidities, caregiver variation, demographics, 
cuff size and location, and patient positioning. 
Other first-line medications to treat sHTN include 
Hydralazine and Nifedipine it would be important 
to study the effects of these medication as well. 
Study investigators plan to apply this study 
methodology to a larger population to compose a 
robust evidence pool to support the current blood 
pressure reassessment protocol or suggest an 
alternative. 
